despit
signific
advanc
vaccin
viru
research
influenza
continu
major
public
health
concern
year
unit
state
america
influenza
virus
respons
season
epidem
result
hospit
death
accur
earli
diagnosi
influenza
viral
infect
critic
rapid
initi
antivir
therapi
reduc
influenza
relat
morbid
mortal
season
epidem
pandem
sever
differ
approach
current
avail
diagnosi
influenza
infect
human
includ
viral
isol
cell
cultur
immunofluoresc
assay
nucleic
acid
amplif
test
immunochromatographybas
rapid
diagnost
test
etc
newer
diagnost
approach
develop
overcom
limit
associ
convent
detect
method
review
discuss
diagnost
approach
current
avail
detect
influenza
virus
human
influenza
also
known
flu
respiratori
ill
caus
virus
belong
famili
orthomyxovirida
famili
consist
four
influenza
viru
genera
influenza
viru
influenza
viru
b
influenza
viru
c
influenza
viru
classifi
base
differ
intern
glycoprotein
nucleoprotein
np
matrix
influenza
type
virus
infect
human
bird
pig
hors
anim
influenza
b
c
virus
found
human
influenza
virus
contain
singl
strand
neg
sens
rna
genom
encod
protein
base
viral
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
influenza
virus
divid
variou
subtyp
ha
na
subtyp
influenza
virus
potenti
form
ha
na
combin
aquat
bird
includ
duck
gees
swan
consid
natur
reservoir
subtyp
year
influenza
virus
influenza
influenza
b
respons
season
epidem
account
hospit
death
per
world
health
organ
estim
influenza
virus
infect
global
popul
annual
result
death
make
lead
caus
mortal
acquir
immun
defici
syndrom
aid
addit
annual
season
epidem
virus
also
result
four
major
influenza
pandem
spanish
flu
asian
flu
hong
kong
flu
recent
pandem
sinc
human
infect
novel
subtyp
highli
pathogen
avian
influenza
hpai
report
first
case
human
infect
influenza
report
hpai
outbreak
poultri
farm
market
hong
kong
result
eighteen
case
six
death
sinc
viru
spread
mani
countri
asia
africa
europ
result
human
case
mortal
rate
greater
addit
avian
influenza
subtyp
also
report
caus
human
infect
recent
strain
infect
human
china
detect
number
diagnost
techniqu
includ
viru
isol
nucleic
acid
amplif
test
naat
immunochromatographybas
rapid
diagnost
test
rdt
etc
use
detect
influenza
virus
human
review
variou
approach
current
avail
develop
diagnosi
influenza
infect
human
recoveri
influenza
virus
clinic
sampl
propag
mammalian
cell
embryon
egg
tradit
method
influenza
diagnosi
introduc
viral
cultur
approach
consid
one
gold
standard
diagnosi
viral
infect
approach
involv
inocul
permiss
cell
line
embryon
egg
infecti
sampl
propag
day
monitor
develop
cytopath
effect
final
confirm
influenza
viru
infect
specif
antibodi
stain
hemadsorpt
use
erythrocyt
immunofluoresc
microscopi
influenza
viru
isol
use
approach
usual
perform
establish
cell
line
madin
darbi
canin
kidney
mdck
mink
lung
epitheli
cell
line
rhesu
monkey
kidney
llc
buffalo
green
monkey
kidney
bgmk
primari
cell
line
rhesu
monkey
kidney
rhmk
african
green
monkey
kidney
agmk
lab
viral
cultur
use
parallel
naat
assay
svc
anoth
viral
cultur
approach
use
sinc
earli
clinic
diagnosi
influenza
viru
infect
approach
involv
propag
virus
mammalian
cell
grown
small
vial
shell
vial
follow
stain
influenza
virusspecif
fluoresc
monoclon
antibodi
svc
approach
rel
straightforward
sensit
compar
tradit
viral
isol
method
viral
detect
possibl
h
modifi
svc
method
use
rmix
cell
mixtur
mink
lung
cell
human
adenocarcinoma
cell
demonstr
higher
sensit
compar
svc
approach
turnaround
time
approxim
day
dfa
test
also
known
immunofluoresc
antibodi
test
ifa
antigenbas
test
routin
employ
diagnosi
influenza
viru
infect
use
sinc
earli
approach
involv
direct
stain
respiratori
epitheli
cell
deriv
nasopharyng
swab
nasopharyng
aspir
fluoresc
label
influenza
virusspecif
antibodi
follow
examin
fluoresc
microscop
due
simplic
assay
procedur
short
turnaround
time
dfa
anoth
studi
evalu
perform
four
test
dfa
chromatograph
influenza
b
viru
immunoassay
shell
vial
cultur
compar
viral
isol
approach
report
assay
sensit
dfa
rapid
test
shell
vial
cultur
modifi
cytospinenhanc
dfa
use
group
enhanc
sensit
dfa
influenza
diagnosi
approach
use
cytospin
protocol
reduc
inadequ
smear
improv
cell
morpholog
increas
assay
sensit
specif
detect
influenza
viru
clinic
sampl
cytospin
dfa
test
show
assay
sensit
compar
cell
cultur
assay
dfa
test
replac
around
world
molecular
approach
sensit
less
labori
clinic
diagnost
laboratori
use
serolog
assay
commonli
use
detect
influenza
virusspecif
antibodi
respons
includ
hemagglutin
inhibit
assay
hai
microneutr
viru
neutral
assay
vn
singl
radial
hemolysi
srh
complement
fixat
assay
enzym
link
immunoabsorb
assay
elisa
western
blot
hai
assay
commonli
use
method
determin
presenc
influenza
viru
haspecif
antibodi
serum
follow
natur
infect
vaccin
human
anim
model
assay
base
abil
haspecif
antibodi
prevent
attach
influenza
viru
approxim
four
hemaggulutin
unit
erythrocyt
obtain
either
chicken
turkey
human
hors
guinea
pig
highest
serum
dilut
prevent
complet
hemagglutin
call
hai
titer
serum
although
assay
simpl
inexpens
sensit
identif
avian
influenza
virus
especi
subtyp
shown
poor
limit
usabl
viru
diagnosi
vn
assay
anoth
techniqu
use
measur
induct
virusspecif
antibodi
follow
natur
infect
vaccin
routin
use
detect
antibodi
titer
either
season
avian
influenza
viru
strain
approach
base
abil
virusspecif
antibodi
neutral
viru
therebi
prevent
viral
infect
cell
reciproc
highest
serum
dilut
viru
infect
complet
block
consid
viru
neutral
titer
although
vn
assay
sensit
compar
hai
assay
applic
routin
diagnost
applic
restrict
due
need
use
infecti
virus
certifi
laboratori
srh
techniqu
commonli
use
determin
induct
antibodi
follow
natur
infect
vaccin
use
measur
complementmedi
hemolysi
induc
antigenantibodi
complex
srh
consid
sensit
hai
assay
requir
pretreat
serum
inactiv
nonspecif
inhibitor
immunodiffusionbas
approach
use
measur
antibodi
respons
influenza
viru
intern
protein
np
follow
vaccin
infect
due
lower
sensit
complement
fixat
replac
hai
vn
eia
assay
elisabas
test
avail
either
solid
microtit
plate
format
paper
strip
format
rapid
test
base
paper
elisa
format
discuss
detail
section
rapid
test
elisabas
test
first
introduc
diseas
diagnos
earli
consist
demonstr
high
sensit
specif
sever
fdaapprov
elisabas
test
avail
diagnosi
sever
bacteri
viral
infect
although
elisabas
test
use
time
one
major
limit
lower
sensit
compar
nucleic
acidbas
test
nat
laboratori
evalu
approach
enhanc
sensit
antigenbas
assay
use
europium
gold
nanoparticl
develop
novel
europium
nanoparticlebas
immunoassay
enia
rapid
detect
influenza
virus
use
monoclon
antibodi
direct
nucleoprotein
influenza
influenza
b
virus
enia
effici
detect
twentynin
differ
strain
influenza
subtyp
ten
differ
strain
influenza
b
furthermor
enia
show
higher
sensit
commerci
avail
photometr
elisa
variou
strain
influenza
b
virus
test
test
nasopharyng
clinic
sampl
flu
season
enia
demonstr
sensit
influenza
virus
influenza
b
virus
specif
ridt
antigenbas
test
develop
rapid
diagnosi
influenza
viru
infect
poc
set
test
use
monoclon
antibodi
target
viral
nucleoprotein
employ
either
enzym
immunoassay
immunochromatograph
later
flow
techniqu
avail
dipstick
cassett
card
format
ridt
complet
less
min
result
observ
visual
base
color
chang
optic
signal
due
simplic
use
speed
obtain
assay
result
ridt
commonli
use
diagnosi
influenza
infect
sever
fdaapprov
ridt
current
avail
market
test
either
detect
distinguish
influenza
b
virus
detect
influenza
virus
influenza
b
virus
discrimin
influenza
b
howev
none
ridt
distinguish
differ
influenza
subtyp
perform
ridt
depend
preval
circul
influenza
virus
popul
peak
influenza
activ
posit
predict
valu
high
fals
posit
therefor
like
observ
howev
low
influenza
preval
neg
predict
valu
high
low
posit
predict
valu
ridt
gener
demonstr
high
specif
detect
season
influenza
viru
infect
diagnosi
season
influenza
infect
ridt
demonstr
variabl
assay
perform
sensit
rang
specif
compar
standard
rtpcrbase
assay
perform
ridt
shown
better
children
compar
adult
approxim
higher
potenti
due
higher
viral
load
longer
viral
shed
children
compar
adult
metaanalysi
studi
involv
commerci
ridt
show
sensit
compar
rtpcr
approach
diagnosi
influenza
infect
season
viru
infect
studi
perform
ridt
detect
influenza
virus
higher
compar
influenza
b
virus
percentag
sensit
influenza
influenza
b
pandem
ridt
demonstr
sensit
rang
compar
rtpcrbase
assay
use
binaxnow
rapid
antigenbas
assay
inver
medic
cologn
germani
drexler
et
al
report
assay
sensit
test
pcrposit
clinic
sampl
bonn
germani
earli
pandem
larg
studi
new
york
report
sensit
use
ridt
binaxnow
influenza
b
test
binaxnow
rapid
detect
flu
ab
test
compar
rmix
cultur
low
sensit
ridt
pandem
could
attribut
poor
sampl
qualiti
inexperi
lab
worker
center
diseas
control
prevent
cdc
studi
evalu
perform
three
differ
ridt
binaxnow
influenza
b
directigen
ez
flu
ab
quickvu
influenza
ab
detect
viru
report
assay
sensit
binaxnow
influenza
b
directigen
ez
flu
ab
quickvu
influenza
ab
compar
rtpcrbase
assay
due
high
rate
fals
neg
cdc
advis
physician
discontinu
antivir
therapi
despit
neg
ridt
result
anoth
studi
quickvu
influenza
ridt
assay
quidel
san
diego
ca
usa
show
assay
sensit
comparison
pcr
assay
anoth
studi
compar
ridt
quickvu
influenza
test
rtpcrbase
assay
report
assay
sensit
specif
posit
neg
predict
valu
studi
respect
studi
compar
ridt
cell
cultur
approach
multiplex
respiratori
viral
assay
luminex
xtag
report
combin
assay
sensit
binax
influenza
ab
inver
scarborough
rapid
detect
flu
ab
medic
diagnost
st
paul
mn
usa
test
nasopharyng
aspir
young
children
one
studi
report
sensit
use
ridt
quickvu
influenza
ab
ict
test
quidel
corp
san
diego
ca
usa
compar
viral
isol
method
detect
avian
influenza
virus
ridt
demonstr
lower
sensit
compar
rtpcrbase
approach
fda
recent
approv
av
avantag
flu
ridt
develop
arbor
vita
corpor
sunnyval
ca
usa
detect
test
use
combin
monoclon
antibodi
pdz
post
synapt
densiti
protein
drosophila
disc
larg
tumor
suppressor
zonula
protein
domain
contain
recombin
protein
detect
protein
throat
swab
complet
min
although
ridt
demonstr
variabl
sensit
still
remain
test
choic
clinic
virolog
laboratori
around
world
due
speed
obtain
result
simplic
assay
procedur
cost
versatil
power
technolog
labonachipmicrochip
loc
provid
new
rout
develop
new
gener
poc
influenza
test
loc
technolog
origin
microelectromechan
system
mem
technolog
focu
chemic
biolog
applic
mani
fascin
advantag
high
reaction
effici
low
reagentenergi
consumpt
low
wast
gener
small
footprint
loc
technolog
util
develop
assay
target
multipl
pathogen
respect
influenza
test
soh
group
report
dispos
microfluid
chip
sampletoansw
genet
analysi
viru
bhattacharyya
klapperich
fabric
plastic
microfluid
solid
phase
extract
devic
isol
viral
rna
mammalian
cell
infect
influenza
viru
recent
report
klapperich
group
describ
dispos
microchip
integr
solidphas
extract
rtpcr
modal
capabl
extract
amplifi
influenza
rna
directli
clinic
specimen
less
three
hour
continuousflow
microfluid
rtpcr
chip
dispos
electr
print
dep
chip
employ
rapid
amplif
sens
swineorigin
influenza
viru
use
rtpcr
chip
method
assay
could
complet
min
signal
detect
dep
chip
miniatur
allinon
realtim
rtpcr
instrument
develop
allow
autom
sampl
prepar
diagnosi
within
h
type
subtyp
season
influenza
demonstr
use
system
anoth
portabl
userfriendli
microchip
nat
system
report
poc
diagnosi
influenza
sensit
close
benchtop
rtpcr
instrument
microchip
electrophoret
immunoassay
coupl
laserinduc
fluoresc
detector
develop
detect
swine
influenza
viru
system
allow
rapid
simultan
concentr
viral
particl
separ
virusantibodi
complex
unbound
antibodi
influenza
assay
implement
use
loc
technolog
microchip
influenza
assay
exhibit
impress
result
howev
effort
system
improv
assay
valid
necessari
adapt
new
loc
test
real
poc
set
develop
polymeras
chain
reaction
pcr
techniqu
kari
mulli
revolution
field
infecti
diseas
diagnosi
nat
also
known
naat
assay
base
pcr
detect
virusspecif
dna
rna
sequenc
genet
materi
rather
viral
antigen
antibodi
test
far
sensit
compar
antigenbas
serolog
test
detect
virus
much
earlier
clinic
sampl
varieti
differ
nat
current
avail
use
diagnosi
influenza
viral
infect
human
includ
revers
transcriptasepcr
rtpcr
ligas
chain
reaction
sequencingbas
test
includ
pyrosequenc
next
gener
sequenc
ng
dna
microarraybas
test
nucleic
acid
sequencingbas
amplif
nasba
loopmedi
isotherm
amplificationbas
assay
lamp
simpl
amplificationbas
assay
samba
transcriptionmedi
amplif
strand
displac
amplif
etc
test
take
h
complet
demonstr
higher
sensit
specif
compar
antigenbas
test
current
fda
licens
nat
avail
influenza
diagnosi
rtpcr
tradit
yet
power
nat
approach
identif
influenza
virus
diagnost
lab
around
world
consid
gold
standard
assay
influenza
diagnosi
rtpcr
involv
three
essenti
step
extract
viral
rna
clinic
specimen
revers
transcript
viral
rna
singlestrand
cdna
use
enzym
revers
transcriptas
amplif
pcr
product
coupl
fluoresc
detect
label
pcr
product
lamp
dna
loopmedi
isotherm
nucleic
acid
amplif
approach
evalu
detect
sever
virus
includ
sever
acut
respiratori
syndrom
sar
corona
viru
rhinoviru
adenoviru
new
castl
diseas
viru
monkey
pox
viru
human
immunodefici
viru
influenza
viru
initi
develop
notomo
et
al
approach
use
novel
dna
polymeras
revers
transcriptas
rna
sampl
high
strand
displac
activ
two
set
primer
special
design
recogn
six
distinct
region
viral
cdna
specif
amplif
target
gene
determin
either
photometr
detect
magnesium
pyrophosph
byproduct
releas
solut
end
reaction
observ
color
chang
follow
addit
sybr
green
lampbas
approach
success
use
detect
influenza
virus
clinic
sampl
sensit
compar
rtpcr
base
assay
use
lampapproach
poon
et
al
report
assay
sensit
detect
season
influenza
virus
subtyp
clinic
sampl
analyt
sensit
assay
copi
per
reaction
furthermor
pandem
realtim
revers
transcript
lampbas
assay
rtlamp
demonstr
sensit
specif
pandem
viru
compar
rtpcrbase
assay
lampbas
assay
also
success
evalu
detect
highli
pathogen
avian
influenza
virus
subtyp
sensit
compar
even
higher
rtpcrbase
approach
parida
et
al
develop
rtlamp
assay
target
gene
code
ha
clinic
diagnosi
viru
rtlamp
assay
perform
better
whoapprov
rtpcr
assay
test
acutephas
throat
swab
sampl
patient
influenzalik
ill
demonstr
higher
sensit
compar
whoapprov
rtpcr
method
analyt
sensit
tcid
ml
median
tissu
cultur
infect
dose
samba
dipstick
isotherm
nucleic
acid
amplif
approach
recent
develop
detect
hiv
influenza
virus
approach
involv
threestep
procedur
consist
viral
rna
extract
target
dna
amplif
use
isotherm
dna
polymeras
detect
amplif
product
use
dipstickbas
system
samba
procedur
take
approxim
two
hour
complet
clinic
perform
approach
evalu
season
avian
influenza
virus
evalu
nasalthroat
nasopharyng
swab
specimen
patient
unit
kingdom
belgium
wu
et
al
report
sensit
respect
influenza
b
virus
compar
rtpcr
approach
analyt
sensit
use
approach
copi
viral
genom
influenza
b
virus
respect
anoth
studi
group
report
assay
sensit
specif
viru
compar
rtpcrbase
approach
base
test
rna
sampl
extract
nasalthroat
swab
specimen
patient
nasba
isotherm
pcrindepend
amplif
method
use
combin
three
enzym
avian
myeloblastosi
viru
revers
transcriptas
rnase
h
rna
polymeras
singl
reaction
nasba
success
evalu
detect
season
influenza
highli
pathogen
avian
avian
influenza
virus
moor
anoth
studi
ge
et
al
use
nasba
rapid
detect
novel
swine
origin
viru
studi
nasba
demonstr
assay
sensit
approxim
copi
per
reaction
compar
higher
observ
commerci
swine
origin
influenza
viru
soiv
realtim
rtpcr
kit
cdc
taqman
assay
recent
wang
et
al
develop
modifi
nasba
procedur
refer
simpl
method
amplifi
rna
target
smart
detect
season
virus
isotherm
amplif
approach
util
singlestrand
dna
ssdna
probe
serv
report
molecul
captur
specif
viral
rna
vrna
sequenc
subsequ
separ
microfluid
chip
zeroflow
condit
smart
assay
demonstr
analyt
sensit
vrna
copiesml
assay
sensit
specif
detect
influenza
virus
microarraybas
approach
proven
use
tool
detect
subtyp
influenza
virus
exampl
fluchip
microarray
lowdens
dna
microarray
shown
detect
strain
hour
similarli
mchip
microarray
demonstr
sensit
specif
identifi
influenza
viru
semiconductorbas
influenza
microarray
develop
combimatrix
corpor
irvin
ca
usa
shown
detect
known
subtyp
influenza
virus
less
five
hour
nanochip
system
nanogen
inc
san
diego
ca
usa
lowdens
microarray
employ
one
probe
conserv
gene
code
probe
cleavag
site
region
ha
gene
shown
use
diagnost
tool
viru
howev
microarraybas
assay
requir
two
enzymat
amplif
step
influenza
viral
rna
prior
hybrid
moreov
detect
requir
label
multipl
probe
incorpor
fluoresc
dyeor
biotinconjug
nucleotid
doublestrand
dna
dsdna
gener
rtpcr
furthermor
sensit
convent
microarray
assay
shown
reli
effici
target
amplif
hybrid
amplicon
probe
multipl
step
involv
assay
make
complex
expens
labor
intens
suscept
contamin
also
make
prone
fals
neg
result
due
presenc
gene
mutat
pcr
inhibitor
rna
degrad
design
multipl
virusspecif
primer
set
assay
optim
procedur
pose
divers
challeng
year
grow
interest
use
nanoparticl
coupl
silver
stain
diagnost
applic
due
greater
sensit
compar
fluoresc
dye
commonli
use
microarray
assay
modifi
approach
allow
rapid
detect
singl
nucleotid
polymorph
snp
human
genom
dna
sampl
without
need
amplif
target
templat
laboratori
develop
nanoparticlebas
genom
microarray
assay
nanomicroarray
specif
identifi
viral
nucleic
acid
simultan
provid
subtyp
identif
influenza
viru
absenc
rtpcr
amplif
procedur
nanomicroarray
system
high
degre
hybrid
effici
assay
specif
method
simpl
use
multipl
oligonucleotid
special
design
target
conserv
region
entir
whole
genom
gene
code
ha
na
influenza
b
virus
approach
vrna
allow
bind
multipl
captur
target
intermedi
oligonucleotid
hybrid
special
gold
nanoparticl
multiplex
oligonucleotidebas
approach
ensur
detect
newlyemerg
strain
undergon
genet
assort
nanomicroarray
assay
use
detect
influenza
b
virus
also
differenti
differ
influenza
viru
strain
season
influenza
also
simultan
detect
subtyp
influenza
virus
singl
assay
use
multipl
sampl
per
slide
analyt
sensit
nanomicroarray
fm
use
purifi
pcr
fragment
tcid
unit
vrna
nanomicroarray
imag
scan
analysi
conclus
viru
ident
drawn
result
seen
specif
intens
pattern
use
nake
eye
combin
next
gener
sequenc
assay
assay
minimallymanipul
procedur
greatli
reduc
number
amplif
omit
fragment
separ
purif
therefor
suitabl
screen
identif
broad
rang
subtyp
influenza
viru
timeand
laboreffici
manner
achiev
final
laboratori
confirm
new
influenza
detect
algorithm
provid
new
way
refin
differenti
diagnos
identif
infect
risk
unknown
influenza
strain
select
singl
test
small
set
test
determin
hpai
strain
clinic
sampl
method
provid
new
tool
accur
diagnos
rapid
identif
season
epidem
pandem
sanger
sequenc
also
refer
dideoxi
procedur
chain
termin
method
dna
sequenc
develop
fredrick
sanger
colleagu
late
approach
involv
use
dna
polymeras
pair
dna
primer
unlabel
deoxynucleotid
triphosph
dntp
chaintermin
dideoxynucleotid
diddntp
base
label
uniqu
fluorophor
select
incorpor
diddntp
newli
synthes
strand
dna
polymeras
inhibit
addit
subsequ
dntp
prevent
elong
target
dna
result
dna
fragment
variou
size
contain
fluoresc
label
ddntp
end
strand
dna
sequenc
determin
base
size
dna
fragment
sequenc
reaction
sequenc
approach
gener
bp
dna
sequenc
read
per
reaction
sanger
sequenc
wide
use
whole
genom
sequenc
influenza
virus
moreov
sanger
sequenc
also
use
detect
antivir
resist
among
circul
influenza
virus
ng
rapidli
expand
technolog
techniqu
may
potenti
gener
enorm
impact
life
scienc
medicin
relat
field
ng
offer
signific
improv
sequenc
speed
throughput
compar
sanger
sequenc
autom
streamlin
workflow
greatli
simplifi
sampl
prepar
sinc
ng
directli
analyz
nucleic
acid
fragment
extract
sampl
obviat
complex
timeconsum
vector
clone
imper
sanger
sequenc
ad
merit
ng
sequenc
cost
expens
sequenc
humans
genom
use
sanger
sequenc
decreas
million
us
dollar
dollar
expect
decreas
near
futur
mani
applic
base
ng
techniqu
emerg
recent
year
focu
mainli
use
diagnosi
influenza
viru
review
encourag
reader
explor
dedic
review
research
articl
compani
websit
detail
inform
ng
platform
ng
technolog
compris
sever
manufacturerspecif
platform
use
differ
sequenc
strategi
reagent
bioinformat
softwar
roch
life
scienc
branford
ct
usa
develop
ng
platform
base
pyrosequenc
highthroughput
sequencingbysynthesi
bioluminesc
method
monitor
realtim
releas
pyrophosph
follow
incorpor
dntp
grow
strand
nascent
dna
sequenc
platform
evalu
diagnost
tool
influenza
research
sever
group
primarili
identif
molecular
marker
drug
resist
among
circul
influenza
virus
bright
colleagu
first
use
platform
studi
incid
adamantin
resist
among
season
influenza
virus
subtyp
isol
worldwid
decad
surveil
signific
increas
drug
resist
observ
studi
highlight
clinic
import
rapid
surveil
antivir
resist
among
circul
season
influenza
viru
strain
sinc
sever
group
success
use
pyrosequenc
platform
identifi
mutat
gene
code
na
respons
resist
adamantan
amantadin
rimantadin
oseltamavir
respect
among
season
highli
pathogen
avian
influenza
virus
pyrosequenc
also
use
group
identifi
snp
gene
code
hemagglutinin
levin
et
al
use
custom
pyrosequenc
protocol
detect
viru
variant
amino
acid
posit
hemagglutinin
known
associ
enhanc
virul
human
recent
lee
et
al
use
pyrosequenc
identifi
mutat
gene
code
ha
na
immunocompromis
child
infect
influenza
viru
treat
oseltamivir
show
use
virochip
microarray
allow
correct
detect
influenza
without
priori
inform
ng
deep
sequenc
techniqu
provid
indepth
knowledg
upper
respiratori
microbiota
host
gene
express
respons
viru
infect
whitehead
et
al
util
illumina
ng
platform
obtain
comprehens
sequencefunct
map
deep
sequenc
optim
influenzabind
protein
base
ng
data
combin
approach
preexist
comput
drug
design
may
open
new
avenu
effici
develop
novel
influenza
inhibitor
altern
ng
platform
besid
roch
illumina
miseq
platform
may
suitabl
influenza
diagnosi
includ
life
technologiesappli
biosystem
ion
person
genom
machin
pgm
ion
proton
solid
ng
platform
pacif
bioscienc
pacbio
rsrsii
singlemolecul
realtim
sequenc
platform
platform
advantag
disadvantag
underli
proprietari
sequenc
techniqu
quit
differ
therefor
crucial
research
select
appropri
ng
platform
meet
specif
need
base
factor
includ
throughput
read
length
error
rate
cost
etc
recent
comparison
studi
report
quail
et
al
may
provid
insight
ng
platform
select
criteria
three
platform
ion
pgm
pacbio
rs
illumina
miseq
employ
sequenc
four
microbi
genom
mean
gc
content
rang
coverag
distribut
bia
gc
distribut
variant
detect
accuraci
use
figur
merit
comparison
author
conclud
three
platform
provid
near
coverag
gcrich
neutral
moder
atrich
genom
howev
systemat
bia
observ
sequenc
extrem
atrich
genom
plasmodium
falciparum
pgm
context
specif
error
identifi
ion
pgm
miseq
data
pacbio
rs
addit
pacbio
rs
limit
yield
high
cost
per
base
prohibit
use
largescal
sequenc
ion
pgm
miseq
equival
util
eas
workflow
recent
lab
demonstr
onetestfitsal
approach
simultan
identifi
unknown
influenza
infect
coinfect
singletub
use
univers
rtpcrng
diagnost
platform
character
influenza
wholegenom
put
antivir
resist
high
virul
marker
may
confer
high
virul
human
host
test
clinic
specimen
demonstr
platform
achiev
highli
sensit
detect
equival
clinic
realtim
rtpcr
rrtpcr
test
low
viru
concentr
allow
multiplex
identif
simultan
discrimin
function
signific
provid
whole
spectrum
influenza
genom
typic
genet
matrix
composit
known
novel
emerg
influenza
infect
determin
develop
ofngsbas
detect
help
uncov
new
level
innov
effici
facilit
futur
use
ng
diagnost
platform
public
health
surveil
antigen
drift
result
accumul
point
mutat
viral
genom
gener
novel
variant
escap
immun
previou
influenza
strain
caus
annual
season
epidem
genet
assort
human
swine
avian
influenza
strain
shown
result
emerg
influenza
virus
novel
ha
andor
na
gene
major
human
popul
lack
immun
diagnost
techniqu
approach
rapidli
accur
detect
newli
emerg
viral
variant
requir
quick
initi
antivir
therapi
prophylaxi
effect
control
infect
season
pandem
outbreak
nat
demonstr
high
specif
sensit
detect
influenza
virus
howev
less
practic
resourcelimit
region
due
high
cost
instrument
complex
requir
wellmaintain
environ
highli
train
profession
larg
number
lowcost
portabl
pointofcar
ridt
base
multipl
mechan
develop
meet
demand
rapidli
diagnos
epidem
pandem
influenza
remot
set
unfortun
ridt
demonstr
variabl
sensit
diagnosi
season
pandem
influenza
viru
infect
furthermor
current
fdalicens
test
influenza
detect
differenti
influenza
b
virus
limit
capabl
subtyp
influenza
virus
henc
newer
approach
costeffect
less
labor
intens
easi
perform
capac
detect
differenti
influenza
virus
also
subtyp
influenza
virus
current
global
public
health
requir
steadi
increas
resist
current
use
na
inhibitor
among
circul
season
novel
avianorigin
influenza
virus
highlight
need
molecular
surveil
put
virul
factor
antivir
resist
marker
improv
public
health
implement
appropri
diagnost
treatment
strategi
season
outbreak
epidem
